BG102999A - New 2,3-diasubstituted-4-(3h)-quinazolinons - Google Patents

New 2,3-diasubstituted-4-(3h)-quinazolinons

Info

Publication number
BG102999A
BG102999A BG102999A BG10299998A BG102999A BG 102999 A BG102999 A BG 102999A BG 102999 A BG102999 A BG 102999A BG 10299998 A BG10299998 A BG 10299998A BG 102999 A BG102999 A BG 102999A
Authority
BG
Bulgaria
Prior art keywords
quinazolinons
diasubstituted
new
neurodegenarativeconditions
diasubstitute
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
BG102999A
Other languages
Bulgarian (bg)
English (en)
Inventor
Mark Elliott
Willard Welch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of BG102999A publication Critical patent/BG102999A/xx
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Paints Or Removers (AREA)
BG102999A 1996-05-15 1998-12-08 New 2,3-diasubstituted-4-(3h)-quinazolinons Pending BG102999A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1773896P 1996-05-15 1996-05-15
PCT/IB1997/000134 WO1997043276A1 (en) 1996-05-15 1997-02-17 Novel 2,3 disubstituted-4(3h)-quinazolinones

Publications (1)

Publication Number Publication Date
BG102999A true BG102999A (en) 1999-09-30

Family

ID=21784266

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102999A Pending BG102999A (en) 1996-05-15 1998-12-08 New 2,3-diasubstituted-4-(3h)-quinazolinons

Country Status (39)

Country Link
US (1) US6303615B1 (zh)
EP (1) EP0901487B9 (zh)
JP (1) JP3241388B2 (zh)
KR (1) KR100375155B1 (zh)
CN (2) CN1103772C (zh)
AP (1) AP1148A (zh)
AR (1) AR007118A1 (zh)
AT (1) ATE242232T1 (zh)
AU (1) AU730503B2 (zh)
BG (1) BG102999A (zh)
BR (1) BR9709085A (zh)
CA (1) CA2252907C (zh)
CZ (1) CZ295565B6 (zh)
DE (1) DE69722613T2 (zh)
DK (1) DK0901487T3 (zh)
DZ (1) DZ2237A1 (zh)
EA (1) EA002905B1 (zh)
ES (1) ES2198546T3 (zh)
GT (1) GT199700049A (zh)
HK (1) HK1019607A1 (zh)
HN (1) HN1997000052A (zh)
HR (1) HRP970261B1 (zh)
HU (1) HUP9902148A3 (zh)
ID (1) ID17149A (zh)
IL (1) IL126589A (zh)
IS (1) IS4881A (zh)
MA (1) MA26430A1 (zh)
NO (1) NO985293L (zh)
OA (1) OA10918A (zh)
PL (1) PL330042A1 (zh)
PT (1) PT901487E (zh)
SI (1) SI0901487T1 (zh)
SK (1) SK284108B6 (zh)
TN (1) TNSN97087A1 (zh)
TR (1) TR199802296T2 (zh)
TW (1) TW539675B (zh)
WO (1) WO1997043276A1 (zh)
YU (1) YU19197A (zh)
ZA (1) ZA974156B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL335307A1 (en) * 1997-02-28 2000-04-10 Pfizer Prod Inc Atropoisomers of 3-heteroaryl-4(3h)-quinazolynes for treating neurodegenerative and traumatic states of central nervous system
ES2219866T3 (es) * 1997-02-28 2004-12-01 Pfizer Products Inc. Atropisomeros de 3-aril-4(3h)-quinazolinonas y su uso como antagonistas del receptor de ampa.
US6060479A (en) * 1997-06-09 2000-05-09 Pfizer Inc Quinazoline-4-one AMPA antagonists
EP0900567A3 (en) * 1997-09-05 2001-05-02 Pfizer Products Inc. Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy
IL125950A0 (en) * 1997-09-05 1999-04-11 Pfizer Prod Inc Methods of administering ampa receptor antagonists to treat dyskinesias associated with dopamine agonist therapy
JPH11279158A (ja) * 1998-02-09 1999-10-12 Pfizer Prod Inc キナゾリン―４―オン誘導体の製造方法
US6825192B1 (en) 1999-02-15 2004-11-30 Eisai Co., Ltd. Heterodiazinone derivatives
US6890930B1 (en) * 1999-09-28 2005-05-10 3-Dimensional Pharmaceuticals, Inc. Quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US20020061897A1 (en) 2000-03-30 2002-05-23 Elliott Richard L. Neuropeptide Y antagonists
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
NZ522773A (en) 2000-06-12 2005-06-24 Eisai Co Ltd 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
AU2002366103A1 (en) 2001-11-19 2003-06-10 Iconix Pharmaceuticals, Inc. Modulators of rho c activity
GB0129260D0 (en) 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
WO2004009036A2 (en) * 2002-07-23 2004-01-29 Cytokinetics, Inc. Compounds compositions and methods
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
MY148809A (en) 2004-07-06 2013-05-31 Eisai R&D Man Co Ltd Crystals of 1,2-dihydropyridine compound and their production process
WO2007056124A2 (en) * 2005-11-04 2007-05-18 Hydra Biosciences, Inc. Compounds for modulating trpv3 function
EP2079739A2 (en) 2006-10-04 2009-07-22 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
AU2008305581C1 (en) * 2007-09-26 2014-12-11 Celgene Corporation 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
WO2009096667A2 (ko) 2008-01-30 2009-08-06 Shin Poong Pharmaceutical Co., Ltd. 신규한 퀴나졸린-2,4-디온 유도체 및 이를 함유하는 뇌신경질환 예방 및 치료용 의약 조성물
JP5794919B2 (ja) 2008-11-13 2015-10-14 ギリアード カリストガ エルエルシー 血液学的な悪性疾患のための療法
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
US8546409B2 (en) 2009-04-20 2013-10-01 Gilead Calistoga Llc Methods of treatment for solid tumors
JP2013500257A (ja) 2009-07-21 2013-01-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋインヒビターでの肝障害の処置
US9216177B2 (en) 2011-02-28 2015-12-22 Drexel University Small molecular inhibitors of RAD51 recombinase and methods thereof
CA2864305C (en) 2012-03-05 2021-02-16 Gilead Calistoga Llc Polymorphic forms of (s)-2-(1-(9h-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3h)-one
US9567337B2 (en) 2013-12-20 2017-02-14 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
WO2015191726A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN113226286B (zh) 2018-12-14 2024-08-20 卫材R&D管理有限公司 1,2-二氢吡啶化合物的水基药物制剂
EP4096661A4 (en) 2020-01-29 2024-03-06 Kamari Pharma Ltd. COMPOUNDS AND COMPOSITIONS FOR USE IN TREATING SKIN DISEASES

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1195321B (de) * 1962-03-16 1965-06-24 Troponwerke Dinklage & Co Verfahren zur Herstellung von substituierten Chinazolon-(4)-derivaten
DE1670416A1 (de) * 1966-12-30 1971-02-11 Chem Fab Von Heyden Gmbh Muenc Verfahren zur Herstellung von aminosubstituierten Chinazolinonderivaten
US3748325A (en) 1970-04-06 1973-07-24 Karamchand Premchand Private Process for the preparation of quinazolinone derivatives
AU543928B2 (en) * 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
GB9022785D0 (en) 1990-10-19 1990-12-05 Merck Sharp & Dohme Therapeutic agents
WO1992013535A1 (en) 1991-02-06 1992-08-20 Research Corporation Technologies, Inc. Anticonvulsant substituted quinazolones
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
DE69401583T2 (de) 1993-05-06 1997-06-12 Novonordisk As [1,2,4-TRIAZOLO[4,3-a]CHINOXALINVERBINDUNGEN DEREN HERSTELLUNG UND VERWENDUNG
GB9400680D0 (en) * 1994-01-14 1994-03-09 Sandoz Ltd Improvements in or relating to organic compounds
ES2219866T3 (es) 1997-02-28 2004-12-01 Pfizer Products Inc. Atropisomeros de 3-aril-4(3h)-quinazolinonas y su uso como antagonistas del receptor de ampa.

Also Published As

Publication number Publication date
YU19197A (sh) 1999-09-27
HRP970261B1 (en) 2003-06-30
DE69722613D1 (de) 2003-07-10
DZ2237A1 (fr) 2002-12-03
IS4881A (is) 1998-10-27
HUP9902148A2 (hu) 2000-04-28
JP3241388B2 (ja) 2001-12-25
WO1997043276A1 (en) 1997-11-20
IL126589A0 (en) 1999-08-17
GT199700049A (es) 1998-10-21
SI0901487T1 (en) 2003-10-31
CZ352698A3 (cs) 1999-11-17
CN1103772C (zh) 2003-03-26
PL330042A1 (en) 1999-04-26
TNSN97087A1 (fr) 2005-03-15
US6303615B1 (en) 2001-10-16
EP0901487A1 (en) 1999-03-17
CA2252907A1 (en) 1997-11-20
AP1148A (en) 2003-02-28
CN1420114A (zh) 2003-05-28
NO985293D0 (no) 1998-11-13
AR007118A1 (es) 1999-10-13
NO985293L (no) 1999-01-13
EP0901487B9 (en) 2004-09-29
SK284108B6 (sk) 2004-09-08
HRP970261A2 (en) 2000-12-31
CA2252907C (en) 2005-05-17
TR199802296T2 (xx) 1999-02-22
KR20000011054A (ko) 2000-02-25
IL126589A (en) 2003-06-24
ZA974156B (en) 1998-11-16
KR100375155B1 (ko) 2003-08-19
PT901487E (pt) 2003-08-29
HN1997000052A (es) 1997-06-26
EA199800923A1 (ru) 1999-06-24
ATE242232T1 (de) 2003-06-15
ID17149A (id) 1997-12-04
JPH11514663A (ja) 1999-12-14
TW539675B (en) 2003-07-01
SK152098A3 (en) 2000-05-16
MA26430A1 (fr) 2004-12-20
AP9701003A0 (en) 1997-07-31
BR9709085A (pt) 1999-08-03
AU730503B2 (en) 2001-03-08
CN1218464A (zh) 1999-06-02
ES2198546T3 (es) 2004-02-01
EP0901487B1 (en) 2003-06-04
AU1554997A (en) 1997-12-05
OA10918A (en) 2001-10-25
DE69722613T2 (de) 2004-05-13
EA002905B1 (ru) 2002-10-31
HK1019607A1 (en) 2000-02-18
CZ295565B6 (cs) 2005-08-17
DK0901487T3 (da) 2003-08-25
HUP9902148A3 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
BG102999A (en) New 2,3-diasubstituted-4-(3h)-quinazolinons
MY131298A (en) 5-heteroyl indole derivatives
NZ332780A (en) Substituted amines for the treatment of neurological and neuropsychiatric disorders
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
ZA961150B (en) Substituted isoxazoles for the treatment of inflammation.
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
IL110204A0 (en) Novel indolene derivatives, processes for their preparation and their use for the treatment of cns disorders
MX9802383A (es) Derivados de pirimidina como antagonistas del receptor 5ht26.
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
WO1993000094A3 (en) Use of tetrahydrobenzazepine derivatives for the treatment of portal hypertension and migraine
BG102589A (en) 3-azetidinylalkylpiperidines or -pyrrolidines as tachykin antagonists
FI974640A0 (fi) Migreenin hoitoon tarkoitetut 1,6-disubstituoidut isokromaanit
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
BG103687A (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative processes and conditions related to the central nervous system
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
BG105962A (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
MY110149A (en) Compounds for the treatment of neurodegenerative disorders
GR3021203T3 (en) Process for the preparation of 1,1,1,2-tetrafluoro-2-chloroethan and pentafluorethane.
BG102667A (en) Diosgenine-containing composition
ZA978640B (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis.
GR3018814T3 (en) Process for the purification of 1,1,1,2-tetrafluoroethane.
EP0692476A3 (de) Verbessertes Verfahren zur Herstellung von N,N'-Carbonyldiazolen, insbesondere N,N'-Carbonyldiimidazol
HU9701060D0 (en) Pharmaceutical composition for treating cognitive disturbs
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу